Skbloom

The New England Journal of Medicine

https://www.nejm.org/doi/full/10.1056/NEJMoa1610020

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Oct 1, 2016 ... Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with ...

https://www.dupixenthcp.com/atopicdermatitis/

DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis ...

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not ...

https://www.dupixent.com/atopicdermatitis/

DUPIXENT® (dupilumab) for Moderate-to-Severe Eczema that is ...

DUPIXENT® (dupilumab) is a subcutaneous injectable prescription medicine for uncontrolled moderate-to-severe eczema (atopic dermatitis) in adults & children ...

https://jamanetwork.com/journals/jamadermatology/fullarticle/2820911

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5 ...

Jul 10, 2024 ... In this open-label extension study of 2677 adults with moderate to severe atopic dermatitis, dupilumab was well tolerated with no new safety incidents and ...

https://www.dupixent.com/atopicdermatitis/about/what-is-eczema

About Eczema (Atopic Dermatitis) | DUPIXENT® (dupilumab)

Eczema (atopic dermatitis) is caused in part by an overactive immune system, which causes more inflammation under the skin than normal.

National Eczema Association

https://nationaleczema.org/eczema/treatment/injectibles/dupixent-faq/

Dupixent for Atopic Dermatitis FAQs | Treatment for Atopic Dermatitis

What is Dupixent? Dupixent is the first biologic medication approved by the FDA for adults and children aged 6+ years with moderate to severe atopic dermatitis.

https://www.dupixent.com/atopicdermatitis/about-dupixent/dosing

How DUPIXENT® (dupilumab) is Taken: Eczema Dosing

DUPIXENT is a prescription medicine used to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD)

https://jamanetwork.com/journals/jamadermatology/fullarticle/2782803

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

Aug 4, 2021 ... Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid ...

PubMed

https://pubmed.ncbi.nlm.nih.gov/34126094/

Management of inadequate response and adverse effects to ...

Jun 11, 2021 ... Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, skin pain, and sleep disturbances. Currently, dupilumab ...

https://www.regeneron.com/downloads/dupixent_fpi.pdf

DUPIXENT Full Prescribing Information

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is ...

Recommendation

Recommendation